2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
US
Corporate
| General Corporate — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Hogan Lovells |
| Latham & Watkins |
| Ropes & Gray |
| WilmerHale |
| General Corporate — Recommended |
|---|
| Arnold & Porter |
| Covington & Burling |
| Dechert |
| Fenwick & West |
| Gibson Dunn & Crutcher |
| Jones Day |
| Morgan Lewis & Bockius |
| Sidley Austin |
| Wilson Sonsini Goodrich & Rosati |
FDA: Medical Device
| FDA: Medical Devices — Highly Recommended |
|---|
| Hogan Lovells |
| Hyman Phelps & McNamara |
| King & Spalding |
| Ropes & Gray |
| FDA: Medical Devices — Recommended |
|---|
| Arnold & Porter |
| Covington & Burling |
| McDermott Will & Emery |
| Morgan Lewis & Bockius |
| Sidley Austin |
FDA: Pharmaceutical
| FDA: Pharmaceutical — Highly Recommended |
|---|
| Covington & Burling |
| Hogan Lovells |
| Hyman Phelps & McNamara |
| Sidley Austin |
| FDA: Pharmaceutical — Recommended |
|---|
| Arnold & Porter |
| King & Spalding |
| Morgan Lewis & Bockius |
| Ropes & Gray |
Healthcare Pricing & Reimbursement
| Healthcare: Pricing & Reimbursement — Highly Recommended |
|---|
| Arnold & Porter |
| Hogan Lovells |
| McDermott Will & Emery |
| Sidley Austin |
| Healthcare: Pricing & Reimbursement — Recommended |
|---|
| Epstein Becker Green |
| King & Spalding |
| Latham & Watkins |
| Morgan Lewis & Bockius |
| Reed Smith |
Licensing & Collaboration
| Licensing & Collaboration — Highly Recommended |
|---|
| Cooley |
| Covington & Burling |
| Goodwin Procter |
| Latham & Watkins |
| Ropes & Gray |
| WilmerHale |
| Wilson Sonsini Goodrich & Rosati |
| Licensing & Collaboration — Recommended |
|---|
| Baker McKenzie |
| Dechert |
| Fenwick & West |
| Hogan Lovells |
| Jones Day |
| King & Spalding |
| Morgan Lewis & Bockius |
| Sidley Austin |
Mergers & Acquisitions
| Mergers & Acquisitions — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Kirkland & Ellis |
| Latham & Watkins |
| Ropes & Gray |
| Skadden Arps Slate Meagher & Flom |
| Mergers & Acquisitions — Recommended |
|---|
| Arnold & Porter |
| Covington & Burling |
| Gibson Dunn & Crutcher |
| Hogan Lovells |
| Sidley Austin |
| WilmerHale |
Product Liability
Venture Capital
| Venture Capital — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Latham & Watkins |
| Wilson Sonsini Goodrich & Rosati |
| Venture Capital — Recommended |
|---|
| Gunderson Dettmer |
| Hogan Lovells |
| Mintz Levin Cohn Ferris Glovsky and Popeo |
| Ropes & Gray |
| WilmerHale |
White-Collar/Govt. Investigations
| White-Collar/Government Investigation — Highly Recommended |
|---|
| Cleary Gottlieb Steen & Hamilton |
| Cooley |
| Covington & Burling |
| Gibson Dunn & Crutcher |
| Hogan Lovells |
| King & Spalding |
| Morgan Lewis & Bockius |
| Ropes & Gray |
| Sidley Austin |
| WilmerHale |
| White-Collar/Government Investigation — Recommended |
|---|
| Arnold & Porter |
| Goodwin Procter |
| Latham & Watkins |
| McDermott Will & Emery |
| Schulte Roth & Zabel |
| White & Case |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Abrams, Steve | Financial & Corporate | Corporate, Mergers & Acquisitions | Philadelphia |
| Church, Robert | Regulatory | FDA: Pharmaceutical, FDA: Medical Device | Los Angeles |
| Colton, Lauren | Non-IP Litigation & Enforcement | Product Liability, White-Collar/Govt. Investigations | Baltimore |
| Connarn, Kristin | Intellectual Property | Patent Prosecution | Boston |
| Diesenhaus, Jonathan | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Washington, D.C. |
| Flaum, Keith | Financial & Corporate | Mergers & Acquisitions | Menlo Park |
| Fox, David M | Regulatory | FDA: Pharmaceutical | Washington, D.C. |
| Gibson, Virginia (Ginny) | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Philadelphia |
| Gilligan, Joseph | Financial & Corporate | Mergers & Acquisitions | Washington, D.C. |
| Golden, Adam H | Financial & Corporate | Corporate, Venture Capital, Licensing & Collaboration, Mergers & Acquisitions | New York City |
| Heyl, Michael | Regulatory | FDA: Medical Device | Washington, D.C. |
| Hogan, Janice M | Regulatory | FDA: Pharmaceutical, FDA: Medical Device | Philadelphia |
| Kahan, Jonathan S | Regulatory | FDA: Medical Device | Washington, D.C. |
| Katyal, Neal | Non-IP Litigation & Enforcement | Product Liability | Washington, D.C. |
| Katz, Philip | Regulatory | FDA: Pharmaceutical | Washington, D.C. |
| Leibenluft, Robert | Non-IP Litigation & Enforcement | Antitrust | Washington, D.C. |
| Levitt, Joseph A | Regulatory | FDA: Medical Device | Washington, D.C. |
| Manning, Meredith | Regulatory | FDA: Pharmaceutical | Washington, D.C. |
| McDavid, Janet | Washington, D.C. | ||
| Mehler, Lynn | Regulatory | FDA: Pharmaceutical | Washington, D.C. |
| Prebula, Randy | Regulatory | FDA: Pharmaceutical, FDA: Medical Device | Washington, D.C. |
| Roberts, Beth L | Regulatory | Healthcare Pricing & Reimbursement | Washington, D.C. |
| Rubin, Asher | Financial & Corporate | Corporate, Venture Capital, Licensing & Collaboration, Mergers & Acquisitions | Baltimore |
| Scott, Jodi | Regulatory | FDA: Medical Device | Denver |
| Smith, John | Regulatory | FDA: Medical Device | Washington, D.C. |
| Spivack, Peter | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Washington, D.C. |
| Sturm, Joy | Regulatory | Healthcare Pricing & Reimbursement | Washington, D.C. |
| Theis, Michael | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Denver |
| Valder Curran, Alice | Regulatory | Healthcare Pricing & Reimbursement | Washington, D.C. |
| Wilder, Marcy | Regulatory | FDA: Medical Device | Washington, D.C. |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Financial & Corporate
Hogan Lovells
With several offices throughout the US and around the globe, Hogan Lovells maintains a strong international presence in the life sciences industry. The firm advises clients in the sector on all matters related to financing, licensing, and transactions. A peer praises the firm for its "excellent, deep knowledge of the life sciences industry."
Based in Baltimore, Asher Rubin is global head of the firm's life sciences group and is highly regarded for advising a variety of life sciences clients in a host of corporate and finance-related matters. In the past year, Rubin led the Hogan team representing NextCure, a biotechnology company focused on cancer and immune-related diseases, with its $86 million IPO as well as a development collaboration with Eli Lilly.
Adam Golden is head of the corporate group in New York, and represents clients in several high-profile transactions as well as collaboration agreements. Golden, who one peer describes as “very strong in the space,” recently advised Novartis in its strategic collaboration agreements with IFM Therapeutics.
Philadelphia-based Steve Abrams assists a variety of life sciences companies with corporate financing, transactions, licensing agreements and collaborations. Among his recent matters, Abrams represented Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) specialists, with its public offering worth $39 million.
Life Cycle
Hogan Lovells
Hogan Lovells is an international firm with a full-service practice in the life sciences area. The firm is notable for its all-encompassing regulatory practice, for which it receives top rankings across the board. The life sciences group also receives national ratings for its practices in general corporate, M&A, licensing and collaboration, venture capital, product liability and white-collar matters.
The firm's top-ranked regulatory practice includes "terrific" partner David Fox, who is highly regarded as an advisor to pharmaceutical companies in FDA clearance. For his stellar career and continued high-profile work in the area, Fox was inducted into the LMG Life Sciences Hall of Fame as part of the 2020 class. Medical device advisor Jonathan Kahan boasts more than 40 years of experience practicing law and is similarly recognized as one of a small group of practitioners in the Hall of Fame. He was recently active for Vayu Global Health Innovations in relation to an Emergency Use Authorization for its bubble CPAP device. In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field, often advising on matters related to the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) drug pricing program. Another standout is Beth Roberts, who earned the 2020 Pricing & Reimbursement Attorney of the Year award for her involvement in a noteworthy National Coverage Determination involving CAR-T therapies.
A peer praises the firm for its "strong regulatory group supporting the transactional practices," and "excellent, deep knowledge of the life sciences industry" as it relates to corporate matters. Baltimore-based Asher Rubin is global head of the firm's life sciences group, who recently led the Hogan team representing NextCure, a biotechnology company focused on cancer and immune-related diseases, with its $86 million IPO as well as a development collaboration with Eli Lilly. Adam Golden is head of the corporate group in New York, and represents clients in several high-profile transactions as well as collaboration agreements. Philadelphia-based Steve Abrams represented Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) specialists, with its public offering worth $39 million.
Jonathan Diesenhaus has extensive experience advising a number of life science clients involving criminal investigations and enforcement matters. Nationally renowned attorney Neal Katyal contributes to the firm’s deep appellate capabilities, often in the product liability space. Lauren Colton serves as head of the firm's products law practice group, offering expertise in mass torts and class actions facing life sciences companies.
Non-IP Litigation & Enforcement
Hogan Lovells
DC-based Hogan Lovells is a global, full-service law firm that is widely considered a juggernaut in the life sciences industry, offering specialized practices focused on antitrust, white-collar defense and regulatory enforcement. The group was shortlisted for the Government Investigations Firm of the Year award in 2020 for significant activity in False Claims Act cases and other matters.
Denver-based Michael Theis leads the firm’s False Claims Act practice group, leveraging his experience as a former trial attorney with Department of Justice to assist clients with investigations and white-collar matters. For his work in the area, Theis was recently shortlisted for the Government Investigations Attorney of the Year award. Jonathan Diesenhaus has extensive experience advising life science clients in criminal investigations and enforcement matters. His practice often involves qui tam matters brought by whistleblowers or government entities. Virginia Gibson is a well-respected trial lawyer who has defended clients from Anti-Kickback Statute claims and other matters related to the False Claims Act. Gibson has a background as a federal prosecutor.
Lauren Colton heads the firm’s product liability group, contributing to the firm’s deep expertise in mass torts and class actions. She is currently acting for Bristol-Myers Squibb as national coordinating counsel in a multidistrict litigation related to the client’s Abilify drug. Recently involved in the product liability space is Neal Katyal, who has earned his status as a leading appellate litigator with a strong track record in life sciences disputes. He recently represented Bristol-Myers Squibb (BMS) and Pfizer in a multi-district litigation, resulting in a Second Circuit ruling that ended the matter in favor of the clients. Prior to his private practice at Hogan Lovells, Katyal served as Solicitor General of the United States.
Regulatory
Hogan Lovells
Co-headquartered in London and Washington DC, Hogan Lovells is consistently ranked for having one of the premier life sciences regulatory practices and is this year’s LMG Life Sciences Regulatory Firm of the Year. One client describes the firm as being "top-notch," with a group of attorneys who possess "a very deep knowledge of the law." The firm's depth gives it the ability to assist a variety of life sciences clients in all aspects of the regulatory process.
David Fox is highly regarded for assisting a number of pharmaceutical companies with their regulatory issues. One peer comments that Fox is "terrific," while another describes him as an "absolute star" in the field. Among his recent matters, Fox served as lead partner representing Intra-Cellular Therapies through the FDA approval process for the company’s Caplyta program, a treatment for schizophrenia.
Operating from both the firm's Washington, DC and Denver offices, Meredith Manning has over 20 years of experience counseling a variety of pharmaceutical clients in regulatory matters. One clients exclaims that Manning and her team "are extremely competent and knowledgeable on FDA regulatory matters" and are "responsive, thorough and able to explain complex rules in an understandable way."
Jonathan Kahan is a "star" according to one peer, and has over 40 years of experience assisting medical device and diagnostics companies with their regulatory issues. He was recently active for Vayu Global Health Innovations in relation to an Emergency Use Authorization for its bubble CPAP device.
In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field with one peer noting she has “great respect” for her work. She regularly advises clients on matters related to the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) drug pricing program. Valder Curran currently serves as chair of the firm's global regulatory practice.
Beth Roberts is this year’s LMG Life Sciences Healthcare Pricing & Reimbursement Attorney of the year and is noted for representing a number of high-profile life sciences clients. One peer notes Roberts is “fantastic” to work with while another peer highlights she “top notch” in the field. Roberts served as lead regulatory counsel for Celgene in a noteworthy NCA matter related to CAR-T therapy.